• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.88% Nasdaq Down0.60%

    Eventide Healthcare & Life Sciences N (ETNHX)

    26.99 Up 0.31(1.16%) Jul 31

    Profile as of Jun 29, 2015Get Profile for:
    Eventide Healthcare & Life Sciences N
    Mutual Fund Series Trust630-a Fitzwatertown Road 2nd FloorWillow Grove, PA19090
    Map
    Phone: 877-771-3836
    Fund Overview 
    Category:Health
    Fund Family:Eventide Funds
    Net Assets:301.73M
    Year-to-Date Return:24.69%
    Yield:0.00%
    Morningstar Rating:N/A
    Fund Inception Date:Dec 27, 2012
    Morningstar Style Box 
    Health
    [View Category Definition]
    View Top Health Funds
    About the Morningstar Style Box
    Management Information 
    Finny Kuruvilla
    Lead Manager since Dec 27, 2012
    Finny Kuruvilla, M.D., Ph.D. Dr. Kuruvilla has been the Managing Partner of Eventide Asset Management, LLC since its inception in 2008. Dr. Kuruvilla possesses a diverse background in quantitative methods, with applications focused on innovations in science, engineering, and medicine. He holds an MD from Harvard Medical School, a PhD in Chemistry and Chemical Biology from Harvard University, a master’s degree in Electrical Engineering and Computer Science from MIT, and a bachelor’s degree from Caltech in Chemistry. From 2005-2008, Dr. Kuruvilla was a clinical fellow at the Brigham and Women's Hospital and a postdoctoral scientist at MIT. As an avid proponent of values-based investing, Dr. Kuruvilla has established rigorous standards in seeking out the most ethical companies at the outset of the stock selection process. In addition to his duties as the Fund’s portfolio manager, Dr. Kuruvilla has also been a Principal at Clarus Ventures since 2008. From 2006-2008, Dr. Kuruvilla was a research fellow at the Broad Institute of Harvard and MIT.
    Investment Information 
    Min Initial Investment:1,000
    Min Initial Investment, IRA:1,000
    Min Initial Investment, AIP:100
    Min Subsequent Investment:50
    Min Subsequent Investment, IRA:50
    Min Subsequent Investment, AIP:50
    ETNHX can be purchased from 25 brokerages.

    Fund Summary 
    The investment seeks to provide long-term capital appreciation. Under normal market conditions, the fund will invest at least 80% of its net assets (plus borrowings for investment purposes) in equity and equity-related securities of companies in the healthcare and life sciences sectors, including common stock, options, preferred stock and convertible debt. It is non-diversified.

    Fund Operations 
    Last Dividend : N/A
    Last Cap Gain : N/A
    Annual Holdings Turnover : 33.00%
    Average for Category:47.77%
    Fees & Expenses 
    ExpenseETNHXCategory Avg
    Annual Report Expense Ratio (net):1.63%1.36%
    Prospectus Net Expense Ratio:1.64%N/A
    Prospectus Gross Expense Ratio:1.70%N/A
    Max 12b1 Fee:0.20%N/A
    Max Front End Sales Load:N/A5.28%
    Max Deferred Sales Load: N/A2.37%
    3 Yr Expense Projection*:530589
    5 Yr Expense Projection*:917905
    10 Yr Expense Projection*:2,0041,781
    * Per $10,000 invested